（来源：CGTN）

转自：CGTN

【从科研到临床：细胞与基因治疗为何需要全球合作助力？】从修复缺陷基因，到改造细胞对抗疾病，细胞和基因治疗（CGT）正为癌症和罕见遗传病等疾病带来新的治疗可能。但要让实验室里的创新真正走向临床、惠及更多患者，技术突破不是最终答案。2026中国细胞与基因治疗大会聚集了来自不同国家的细胞和基因治疗领域的专家，其中来自美国、中国和加拿大的专家同CGTN分享了他们对于细胞和基因治疗的原理和应用前景的观察。他们指出，中国在该领域发展迅速，前景广阔。专家们表示，通过共享临床信息、科研成果和先进技术，不同国家可以发挥各自优势，加速临床研究与药物开发，同时探索降低治疗成本的新路径。From repairing faulty genes to reprogramming cells to fight disease, cell and gene therapy, also known as CGT, is pushing medicine into a new frontier and opening new possibilities for people living with cancer, rare genetic disorders and diseases once seemed unbeatable.At the 2026 Annual Meeting of China Society of Gene and Cell Therapy (CSGCT), scientists and industry experts from China, the United States and Canada shared their views with CGTN on where the CGT is heading.In this episode of Health Talk, experts underline the growing potential of the CGT while pointing to something that may matter just as much as scientific innovation: diseases recognize no borders, thus we need collaboration across borders.Patients, data, technologies and ideas rarely exist in one place. By pooling patient resources, sharing research and technological advances and drawing on different strengths, countries can help accelerate clinical trials and drug development – and potentially make these groundbreaking therapies more accessible and affordable.